UMC Reports Sales for April 2025
TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) ('UMC'), today reported unaudited net sales for the month of April 2025.
Revenues for April 2025
Period
2025
2024
Y/Y Change
Y/Y (%)
April
20,454,530
19,741,391
713,139
3.61%
Jan.-Apr.
78,313,487
74,373,490
3,939,997
5.30%
Expand
(*) All figures in thousands of New Taiwan Dollars (NT$), except for percentages.
(**) All figures are consolidated
Additional information about UMC is available on the web at https://www.umc.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Verint Genie Bot Delivers Millions of Dollars in Business Value
MELVILLE, N.Y., June 12, 2025--(BUSINESS WIRE)--Verint® (NASDAQ: VRNT), The CX Automation Company™, today announced AI business outcomes customers achieved with the recently launched Verint Genie Bot. Part of Verint Open Platform's business analytics solutions, Verint Genie Bot is supercharging business analyst capacity. The bot delivers critical customer experience (CX) insights to executives at unprecedented speed across customer complaints, churn, upsell opportunities and cost reduction initiatives. Verint Genie Bot Delivers Powerful AI Business Outcomes The AI-powered bot delivers actionable CX insights in minutes, driving millions of dollars in value to customers across industries. For example, in the first day of using Verint Genie Bot, an international financial institution uncovered the insights to optimize customer journeys, reduce costs and increase revenue by $5 million. In addition, an energy provider leveraged the bot's insights to streamline self-service and agent workflows, opening the door to $3 million in cost reduction. "Our latest release of Verint Genie Bot is another breakthrough in applying agentic AI to CX Automation," said Verint's Global Vice President, Product and Go-to-Market Strategy, Daniel Ziv. "By combining the latest generative and agentic AI capabilities, Verint Genie Bot is now proven to create unparalleled value." Discover how Verint Genie Bot and Verint Open Platform can unlock transformative insights and AI outcomes, now. About Verint Verint® (NASDAQ: VRNT) is a leader in Customer Experience (CX) Automation, serving a customer base that includes more than 80 of the Fortune 100 companies. The world's most iconic brands use the Verint Open Platform and our team of AI-powered bots to deliver tangible AI Business Outcomes, Now™ across the enterprise. Verint is uniquely positioned to help brands increase CX Automation with our differentiated, AI-powered Open Platform. Verint, The CX Automation Company™, is proud to be Certified™ by Great Place To Work®. Learn more at This press release contains "forward-looking statements," including statements regarding expectations, predictions, views, opportunities, plans, strategies, beliefs and statements of similar effect relating to Verint Systems Inc. These forward-looking statements are not guarantees of future performance and they are based on management's expectations that involve a number of risks, uncertainties and assumptions, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. For a detailed discussion of these risk factors, see our Annual Report on Form 10-K for the fiscal year ended January 31, 2025, and other filings we make with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release and, except as required by law, Verint assumes no obligation to update or revise them or to provide reasons why actual results may differ. VERINT, VERINT DA VINCI, VERINT OPEN CCAAS, THE CX AUTOMATION COMPANY, THE CUSTOMER ENGAGEMENT COMPANY AND THE ENGAGEMENT CAPACITY GAP are trademarks of Verint Systems Inc. or its subsidiaries. Verint and other parties may also have trademark rights in other terms used herein. View source version on Contacts Media Relations Andi Investor Relations Matthew Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24 minutes ago
- Yahoo
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
Most of UnitedHealth Group's issues should be temporary. The two biggest threats to the healthcare giant are iffy. The price is right to buy UnitedHealth Group stock after its steep decline. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 HSBC Holdings is an advertising partner of Motley Fool Money. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends HSBC Holdings and UnitedHealth Group. The Motley Fool has a disclosure policy. Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Netflix has a solid plan to become a trillion-dollar company by 2030. Veeva Systems still has a massive addressable market. 10 stocks we like better than Netflix › Broader equities have not performed particularly well in 2025. The S&P 500 is barely in the black year to date. However, considering it hovered near bear market territory a few weeks ago, things aren't so bad. Stocks might not be out of the woods, though. Economic issues could arise, sending markets down, as the Trump administration continues to implement its trade agenda. That said, regardless of what happens on that front, there are plenty of companies worth investing in. Here are two great examples: Netflix (NASDAQ: NFLX) and Veeva Systems (NYSE: VEEV). Netflix, a streaming specialist, has been grabbing headlines recently for all the right reasons. The stock is up for the year, financial results have been good, and management sees significant upside ahead. The company has plans to join the exclusive club of trillion-dollar stocks by 2030. From its current market cap of $522 billion, that will require a compound annual growth rate of 13.9%. That's nothing to sneeze at, but it's well within the company's reach, in my view. Five years ago, Netflix ended 2019 with $20.2 billion in revenue. Last year, that had risen to $39 billion -- a compound annual growth rate (CAGR) of 14.1%. True, a lot has changed since. There is more competition in the streaming field, for instance. Even so, Netflix has made changes that have kept it in the lead in the industry, including a crackdown on password sharing and the introduction of a low-priced ad-supported tier. The company doesn't grow its revenue quite as fast as it used to, but in the past five years, profits and free cash flow have soared. Meanwhile, there is still considerable room for growth in the streaming industry. Netflix's estimate of a $650 billion revenue opportunity reflects the fact that streaming still has yet to completely overtake entertainment. The industry's penetration should expand over the long run and benefit Netflix, considering its strong position, network effect, and brand name. Furthermore, it is increasingly using artificial intelligence (AI) to enhance its content strategy, which is already a key to its success. Though AI won't be the center of Netflix's universe, it can allow the company to make better movies for less money, something that will make a difference down the road. So the goal to achieve a trillion-dollar valuation in the next five years isn't just a pipe dream -- it is well within the company's powers. Even if it fails, though, the stock should deliver superior returns well beyond 2025. Veeva Systems isn't the biggest player in the cloud industry. That title arguably goes to Amazon, with other tech giants, such as Alphabet and Microsoft, not far behind. However, Veeva Systems is a leader in a niche within the industry. It offers cloud solutions primarily to life science companies such as drugmakers. The fact that the company's list of clients features some of the largest pharmaceutical players, including Merck, Novo Nordisk, and Eli Lilly, is telling. The company is doing something right. Here's what that thing is: It has developed a wealth of cloud services specifically catered to the stringent regulatory (and other) demands of the industry. Generic solutions won't do for many of these companies. Enter Veeva Systems. The cloud computing specialist's financial results also reflect its success. Revenue and earnings have been growing at a good clip. And when management set revenue goals to be achieved by a certain date in the past, Veeva has met the goal. It recently hit its $3 billion revenue run-rate target -- which, in 2019, it said it would achieve by the calendar year 2025. That's a management team investors can trust. Many CEOs overpromise and underdeliver. Meanwhile, Veeva still has plenty of white space ahead, with an estimated $20 billion addressable market. Revenue over the trailing-12-month period is $2.9 billion. Given the high switching costs, the company should remain a strong player in this niche for some time as it continues to make headway in its market. It could encounter some headwinds if the economy tanks, as it did a couple of years ago. But the company has recovered nicely since -- a microcosm of what its performance might look like over the long run. Even with occasional slowdowns, expect Veeva Systems to deliver above-average returns in the next decade. Before you buy stock in Netflix, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Netflix wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Amazon, Eli Lilly, and Novo Nordisk. The Motley Fool has positions in and recommends Alphabet, Amazon, Merck, Microsoft, Netflix, and Veeva Systems. The Motley Fool recommends Novo Nordisk and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility was originally published by The Motley Fool
